Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda

May 9, 2023: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
  (Public Comment Prior to Board Action**)**

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Chief Medical Officer Updates** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
  - Data presentation: Use of Warfarin with Antibiotics
  - Introduce: Chronic Use of Sedatives/Hypnotics

- **Clinical Update: Drug Reviews** **7:20-7:40**
  (Public comment prior to Board action)

  Biosimilar Drug Reviews
  - Fylnetra® (pegfilgrastim-pbbk) biosimilar to Neulasta and Stimufend® (pegfilgrastim-pbbk) biosimilar to Neulasta

  Full New Drug Reviews
  (Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

  - Auvelity® (dextromethorphan- bupropion)
  - Relyvrio® (sodium phenylbutyrate and taurursodiol)
  - Rolvedon® (eflapegrastim-xnst)
  - Ryaltris® (olopatadine hydrochloride and mometasone)
  - Xaciato Gel® (clindamycin phosphate)

- **New Managed Therapeutic Drug Classes** **7:40 -7:50**
  - None at this time.

  (Public comment prior to Board action)
  - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:50 - 8:20**
  (Public comment prior to Board action)
  - Analgesics: Short Acting Opioids
  - Analgesics: Long Acting Opioids
  - Antipsychotics
  - Epinephrine Autoinjectors
  - Hepatitis B
  - Hepatitis C
  - Neuropathic Pain/Fibromyalgia
  - PAH (new drug Tadliq® (tadalafil) included)
  - Topical Corticosteroids

- **Review of Newly Developed/Revised Criteria** **8:20 - 8:20**
  (Public comment prior to Board action)

- **General Announcements** **8:20 – 8:30**

  FDA announces new safety label changes for opioid pain medicines
  https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-new-safety-label-changes-opioid-pain-medicines

  FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena
  https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena

- **Adjourn** **8:30**